30-Day Morbidity and Mortality of Bariatric Surgery During the COVID-19 Pandemic: a Multinational Cohort Study of 7704 Patients from 42 Countries

Rishi Singhal1 • Christian Ludwig2 • Gavin Rudge3 • Georgios V. Gkoutos4,5,6,7 • Abd Tahranı2,8,9 • Kamal Mahawar10 • on behalf of the GENEVA Collaborators • Michał Pędzwiat • Piotr Major • Piotr Zarzycki • Athanasios Pantelis • Dimitris P. Laptasnis • Georgios Stravodimos • Chris Matthys • Marc Focquet • Wouter Vleeschouwers • Antonio G Spaventa • Carlos Zerrerweck • Antonio Vitiello • Giovanna Berardi • Mario Musella • Alberto Sanchez-Meza • Felipe J. Cantú Jr • Fernando Mora • Marco A. Cantu • Abhishek Katakwar • D. Nageshwar Reddy • Haitham Elmaleh • Mohammad Hassan • Abdelrahman Elghandour • Mohey Elbanna • Ahmed Osman • Athar Khan • Laurent Layani • Nalini Kiran • Andrey Velikorechin • Maria Solovyeva • Hamid Melali • Shahab Shahahi • Ashish Agrawal • Apoorv Shrivastava • Ankur Sharma • Bhavya Narwaria • Mahendra Narwaria • Asnat Raziel • Nasser Sakran • Sergio Susmallian • Levent Karagöz • Murat Akbaba • Salih Zeki Pişkin • Ahmet Ziya Balta • Zafer Senol • Emilio Manno • Michele Giuseppe Iovino • Ahmed Osman • Mohamed Qassem • Sebastián Arana-Garza • Heitor P. Povoas • Marcos Leão Vilas-Boas • David Naumann • Jonathan Super • Alan Li • Basil J. Ammori • Hany Balamoun • Mohammed Salman • Amrit Manik Nasta • Ramen Goel • Hugo Sánchez-Aguilar • Miguel F. Herrera • Adel Abou-Mrad • Lucie Cloix • Guilherme Silva Mazzini • Leonardo Kristem • Andre Lazaro • Jose Campos • Joaquín Bernardo • Jesús González • Carlos Trindade • Octávio Viveiros • Rui Ribeiro • David Goitein • David Hazzan • Lior Segev • Tamar Beck • Hernán Reyes • Jerónimo Monterrubio • Paulina García • Marine Benois • Radwan Kassir • Alessandro Contine • Moustafa Elshafei • Sueleyman Aktas • Sylvia Weiner • Till Heidsieck • Luis Level • Silvia Pinango • Patricia Martinez Ortega • Rafael Moncada • Victor Valenti • Ivan Vlahović • Zdenko Boras • Arnaud Liagre • Francesco Martini • Gildas Juglard • Manish Motwani • Sukhvinder Singh Saggu • Hazem Al Moman • Luis Adolfo Acives López • Maria Angelina Contreras-Cortez • Rodrigo Acives Zavala • Christine D’Haese • Ivo Kempeneers • Jacques Himpens • Andrea Lazzati • Luca Paolino • Sarah Bathaei • Abdulkadir Bedirli • Aydın Yavuz • Çağrı Büyükkasap • Safa Özaydın • Andrzei Kwiatkowski • Katarzyna Bartosiak • Maciej Walędzjak • Antonella Santonicola • Luigi Angrisani • Paola Iovino • Rossella Palma • Angelo Iossa • Cristian Eugeniu Boru • Francesco De Angelis • Gianfranco Silecchia • Abdulzahra Hussain • Srivinasan Balchandra

Key Points
499 surgeons from 185 centres in 42 countries submitted complete data on 7704.
BS can be safely performed during the pandemic with morbidity and mortality similar to what was seen before the pandemic.
The risk of developing symptomatic COVID 19 post-BS is low.
Local COVID-19 incidence can affect incidence of post-BS symptomatic COVID-19.

Rishi Singhal
singhal_rishi@hotmail.com

1 Upper GI unit, University Hospital Birmingham NHS Foundation Trust, Birmingham, UK
2 Institute of Metabolism and Systems Research (IMSR), College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK
3 Institute of Applied Health Research, Murray Learning Centre, University of Birmingham, Birmingham, UK
4 Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK
5 NIHR Biomedical Research Centre, Birmingham B15 2TT, UK
6 NIHR Surgical Reconstruction and Microbiology Research Centre, Birmingham B15 2TT, UK
7 MRC Health Data Research UK (HDR), Midlands Site, UK
8 Centre for Endocrinology, Diabetes and Metabolism (CEDAM), Birmingham Health Partners, Birmingham, UK
9 Department of Diabetes and Endocrinology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
10 Bariatric Unit, South Tyneside and Sunderland NHS Trust, Sunderland, UK
Introduction

The coronavirus disease 2019 (COVID-19) pandemic has put a severe strain on global healthcare resources. This along with the realisation that perioperative severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is associated with high 30-day mortality (23.8%) [1] led to the cancellation of millions of elective and semi-urgent surgical procedures worldwide, including bariatric and metabolic surgery (BS) [2].

It is also known that patients who inadvertently underwent BS before the scale of the pandemic became fully apparent and developed perioperative SARS-CoV-2 infection suffered significant morbidity [3]. There were hence genuine concerns that the morbidity and mortality of BS might be higher during the pandemic. This led to several consensus statements and guidelines on the safe resumption of BS [4–6]. The effect of adoption of these consensus statements on the morbidity and mortality of BS was, however, unknown. Knowledge of the factors that are associated with morbidity and postoperative COVID-19 infection might further allow us to improve our recommendations for safe BS during the pandemic.

Recommendations for safe surgery during the pandemic include routine preoperative reverse-transcriptase polymerase chain reaction (RT-PCR) testing for SARS-CoV-2 and/or preoperative self-isolation for variable time durations [7–11]. Studies from cancer surgery further suggest that a negative preoperative RT-PCR or operating in hospitals that have “coronavirus disease (COVID-19) free” surgical pathways (complete segregation of the operating theatre, critical care, and inpatient ward areas) is associated with a lower rate of postoperative pulmonary complications [12, 13]. However, data regarding the safety of non-cancer surgery such as BS during the COVID-19 pandemic and whether the above-mentioned pathways result in safer BS outcomes is unknown.

Associations between obesity and severe COVID-19 [14, 15]; patients’ concerns regarding the availability and safety of BS during the pandemic [16, 17]; and the negative impact of the pandemic and lockdowns on the health and eating and physical activity behaviours [18] further make it important to examine the safety of BS during the COVID-19 pandemic.

We, therefore, conducted an international cohort study — the global 30-day outcomes of bariatric surgery iN thE coVid-19 erA (GENEVA) to capture 30-day morbidity and mortality of BS performed between 01/05/2020 and 31/10/2020. Four hundred ninety-nine surgeons from 185 centres in 42 countries provided data on 7704 patients. Elective primary BS (n = 7084) was associated with a 30-day morbidity of 6.76% (n = 479) and a 30-day mortality of 0.14% (n = 10). Emergency BS, revisional BS, insulin-treated type 2 diabetes, and untreated obstructive sleep apnoea were associated with increased complications on multivariable analysis. Forty-three patients developed symptomatic COVID-19 postoperatively, with a higher risk in non-whites. Preoperative self-isolation, preoperative testing for SARS-CoV-2, and surgery in institutions not concurrently treating COVID-19 patients did not reduce the incidence of postoperative COVID-19. Postoperative symptomatic COVID-19 was more likely if the surgery was performed during a COVID-19 peak in that country.

Conclusions BS can be performed safely during the COVID-19 pandemic with appropriate perioperative protocols. There was no relationship between preoperative testing for COVID-19 and self-isolation with symptomatic postoperative COVID-19. The risk of postoperative COVID-19 risk was greater in non-whites or if BS was performed during a local peak.

Keywords COVID-19 · SARS-CoV-2 · Pandemic · Bariatric surgery · Obesity surgery · Revisional surgery
monitor practice to ensure the safety of BS and explore predictors of complications and postoperative COVID-19.

As a result, we continued to collect data and expanded the study to include 5703 more patients’ data submitted by 281 more surgeons from 58 more centres in 7 more countries. The study hypothesis was that the 30-day morbidity and mortality of BS performed globally during the COVID-19 pandemic would be similar to the pre-pandemic figures. The study’s primary outcome measure was all-cause and COVID-19-specific 30-day morbidity and mortality of BS. Secondary outcome measures were predictors of BS complications during the pandemic and the effect of preoperative testing, preoperative self-isolation, hospital protocols, and local pandemic burden on postoperative COVID-19 rates.

Methods

Study Design and Population

We conducted a global, multicentre, observational cohort study of BS (elective primary, elective revisional, and emergency) in adults (≥ 18 years) performed between 1/05/2020 and 31/10/2020. The study start date was 1st May to exclude patients who underwent BS before the full scale of the pandemic and its effect on surgical patients became widely known.

We included all consecutive adult patients undergoing elective BS between 1st May and 31st October 2020 regardless of the surgical approach or the patient’s preoperative COVID-19 status. All laparoscopic, open, robotic, or hybrid surgical procedures were included. Laparoscopic sleeve gastrectomy, Roux-en-Y gastric bypass, and one anastomosis gastric bypass procedures were identified separately, whereas all others were pooled together in the “others” category. Procedures included in the “others” category were a range of diverse bariatric procedures. Data was also collected for patients undergoing emergency surgery related to previous bariatric surgery. The participating centres and surgeons were contacted using personal networks and national professional BS societies (via newsletters, email, and social media groups such WhatsApp®, and bariatric professionals’ networks on LinkedIn®, Facebook®, and Twitter®).

This project was registered as a multinational audit (number: 5197) at the University Hospitals Birmingham NHS Foundation Trust, UK. Each site project lead was responsible for obtaining local governance approvals and data sharing agreements before entering data into the registry. Patient’s approval to share their anonymised data was obtained by the individual collaborators and it was the responsibility of the site leads to ensure that patient approval was in place and documented in the notes before entering data into the registry. The site leads had to agree to these terms electronically before they were allowed access to the registry to enter data.

Data Collected and Handling

Data collection included patients’ demographics, details of surgery performed, preoperative COVID-testing protocols and outcomes, in-hospital and 30-day COVID-19, and surgery-specific morbidity and mortality. If a patient developed more than one complication, additional questions had to be completed for each complication. This information was collected using 77 questions (supplementary file).

Complications were captured using the Clavien-Dindo (CD) classification system [20] for reporting surgical complications. This allowed for easier comparison of complication data and captured all complications irrespective of their severity. We further captured individual complications that would be important to the bariatric community such as bleeding and leak rates and complications such as chest infection/pneumonia that would be important in the context of the COVID-19 pandemic. In case of more than one complication occurring in the same patient, the highest CD score was reported.

Data collected regarding the centre and the surgeon were organised in 73 questions and included extensive profiling of the centre, the surgeon, and the impact and handling of COVID-19 in that centre. A copy of the questions can be found in the appendix.

Study data were collected and managed using REDCap electronic data capture tools hosted at the University of Birmingham, UK. REDCap (Research Electronic Data Capture) is a secure, web-based software platform designed to support data capture for research studies [21, 22].

Data entered on REDCap were examined weekly for any missing or erroneous data throughout the study period, and site leads were contacted for clarification. Collaborators were routinely contacted at 32 days following surgery if the 30-day follow-up data had not been completed. The final dataset was downloaded on the 10th of December once data queries had been resolved. Data was subsequently re-examined for omissions or abnormalities.

Statistical Methods

Continuous data were presented as mean ± standard deviation (SD) or median (IQR) depending on data distribution. Frequencies were used to summarise categorical variables. Independent t-test or Mann-Whitney U test was used to examine differences between continuous variables depending on data distribution. A Chi-square test was used to compare categorical variables. Statistical analysis was performed using Statistical Package for the Social Sciences (SPSS) statistical software, version 27.0 (SPSS Inc).
A total of 499 surgeons from 185 centres in 42 countries submitted data on 7734 patients who underwent BS between 1st May 2020 and 31st October 2020 at the participating centres. Of these, complete 30-day morbidity and mortality data were available for 7704 (99.6%) by the 10th of December 2020. Table 1 provides the basic demographics of these patients. Most patients (7084, 91.9%) underwent elective primary BS while 449 (5.8%) and 171 (2.2%) patients underwent elective revisional BS and emergency surgery following a previous BS respectively. The primary surgery population mainly consisted of young white females (5197; 73.4%) with severe obesity and a high prevalence of obesity comorbidities; a quarter of the study population were non-whites (1813; 25.59%).

Of patients undergoing primary BS, laparoscopic sleeve gastrectomy (LSG), laparoscopic Roux-en-Y gastric bypass (LRYGB), and laparoscopic one anastomosis gastric bypass (LOAGB) were performed in 3988 (51.8%), 2091 (14.2%), and 705 (9.2%) patients, respectively. Three hundred (3.9%) patients underwent “others” procedures. Other procedures included a range of diverse bariatric surgical procedures and also procedures performed using open, robotic, and hybrid surgical approaches.

### 30-Day Morbidity and Mortality (Table 2)

Four hundred seventy-nine (6.76%) patients undergoing primary BS developed at least one complication. Of these, 302 (4.26%) were minor CD grade I or II; and 177 (2.5%) were CD grade III, IV, or V. Overall, 49 (0.69%) patients required management in intensive care (CD grades IV and V). Ten (0.14%) patients died. Although complication rates were higher in patients undergoing elective revisional surgery (n = 53/449, 11.8%) and those undergoing emergency surgery (n = 35/171, 20.46%) compared to primary BS, no deaths were reported for these groups.

Factors affecting complications have been described in Table 3. On logit regression analysis, increasing age, male sex, being a current or former smoker (vs. non-smoker), having insulin-dependent type 2 diabetes (T2D; vs. patients who did not have diabetes), obstructive sleep apnoea (OSA) not on continuous positive airways pressure (CPAP) (vs. patients did not have OSA), hypertension, and hypercholesterolaemia were associated with increased complication levels. Emergency procedures and revisional procedures were associated with higher odds of increased complications, as was primary LRYGB or other primary procedures as compared to primary LSG. Prior experience of the surgeon also appeared significant.

Of the 10 patients who died [5 LSG, 4 LOAGB, and 1 laparoscopic single anastomosis duodeno-ileal bypass patient], seven (70.0%) were females. Four of these died due to leaks (3 following LOAGB and 1 following LSG), two died due to pulmonary embolism (PE), one died of COVID-19 pneumonia with PE, one died of mesenteric thrombosis, one died of bleeding, and one died of multi-organ failure (not otherwise specified; further data was not available for this patient).

The patient who was diagnosed with COVID pneumonia postoperatively had been advised to self-isolate for 2 weeks preoperatively and also had a negative RT-PCR preoperatively. Of the remaining 9 patients, 3 (33.3%) had been advised preoperative self-isolation; 6 (66.6%) had preoperative testing for SARS-CoV-2.

### Perioperative COVID-19 Protocols (Table 4)

Owenill, 54% (n = 4068) of elective (primary and revisional) patients were not recommended any preoperative self-isolation. Similarly, 19.8% (n = 1491) of the patients did not undergo any preoperative testing to rule out SARS-CoV-2 infection. One hundred thirty-six out of 185 centres indicated that they were treating COVID-19 patients in the same hospitals (6086 patients; 79%), as opposed to 49...
| Table 1 | Basic demographic details of all patients undergoing elective primary BS, elective revisional BS, and emergency procedures |
|--------|----------------------------------------------------------------------------------|
|        | Elective primary surgery | Elective revisional surgery | Emergency surgery |
|        | All primary procedures | LSG | RYGB | OAGB | Others* | All revisional procedures | Conversional surgery | Other revisional procedures |
| Total number | 7084 | 3988 | 2091 | 705 | 300 | 449 | 285 | 164 | 171 |
| Age | 40.35 ± 11.9 | 38.78 ± 11.9 | 43.01 ± 11.4 | 41.13 ± 11.3 | 40.86 ± 11.9 | 44.81 ± 10.9 | 43.76 ± 10.9 | 46.64 ± 10.7 | 45.29 ± 11.9 |
| Sex (M: F) | 1886 (26.6%): 5197 (73.4%) | 1100 (27.6%): 2888 (72.4%) | 496 (23.7%): 1594 (76.2%) | 208 (29.5%): 497 (70.5%) | 82 (27.3%): 218 (72.7%) | 84 (18.7%): 365 (81.3%) | 56 (19.6%): 229 (80.4%) | 136 (82.9%): 27 (15.8%) | 144 (84.2%) |
| Weight (in kg) | 119.49 ± 24.4 | 119.51 ± 25.6 | 118.81 ± 21.2 | 122.46 ± 26.1 | 116.91 ± 25.2 | 104.35 ± 24.8 | 108.1 ± 24.1 | 97.85 ± 24.6 | 87.54 ± 24.8 |
| BMI | 43.03 ± 6.9 | 43.14 ± 7.4 | 42.52 ± 5.7 | 44.19 ± 7.5 | 42.29 ± 7.8 | 38.05 ± 8.8 | 39.51 ± 8.6 | 35.52 ± 8.6 | 31.08 ± 7.9 |
| Ethnicity data | | | | | | | | | |
| White | 5271 (74.41%) | 3018 (75.68%) | 1445 (69.11%) | 541 (76.74%) | 267 (89%) | 374 (83.3%) | 232 (81.4%) | 142 (86.59%) | 155 (90.64%) |
| Non-white*** | 1813 (25.59%) | 970 (24.32%) | 646 (31.89%) | 164 (23.26%) | 33 (11%) | 75 (16.7%) | 53 (18.6%) | 22 (13.41%) | 16 (9.36%) |
| Asian | | | | | | | | | |
| Black or African | | | | | | | | | |
| American | 398 (5.62%) | 184 (4.61%) | 34 (1.63%) | 92 (13.05%) | 14 (4.67%) | 19 (4.23%) | 13 (4.56%) | 6 (3.66%) | 2 (1.17%) |
| Hispanic or Latino | 87 (1.23%) | 51 (1.28%) | 500 (23.91%) | 0 (0%) | 17 (5.67%) | 45 (10.02%) | 35 (12.28%) | 10 (6.1%) | 7 (4.09%) |
| Native Hawaiian or other | 1394 (18.41%) | 716 (17.95%) | 1 (0.05%) | 0 (0.02%) | 1 (0.22%) | 0 (0.00%) | 0 (0.00%) | 0 (0.00%) | 0 (0.00%) |
| Pacific Islander | 14 (0.2%) | 12 (0.3%) | 3 (0.14%) | 0 (0.00%) | 0 (0.00%) | 0 (0.00%) | 0 (0.00%) | 0 (0.00%) | 0 (0.00%) |
| American Indian or Alaska Native Co-morbidity data | | | | | | | | | |
| Any co-morbidity | 4879 (68.9%) | 2546 (63.86%) | 1555 (74.37%) | 564 (80.11%) | 214 (71.33%) | 260 (57.91%) | 178 (62.46%) | 82 (50%) | 74 (43.27%) |
| Type 2 diabetes | 421 (5.9%) | 205 (5.14%) | 109 (5.21%) | 76 (10.8%) | 31 (10.33%) | 18 (4.01%) | 9 (3.16%) | 9 (5.49%) | 7 (4.09%) |
| Oral medication | 860 (12.1%) | 392 (9.83%) | 296 (14.16%) | 113 (16.05%) | 59 (19.67%) | 34 (7.57%) | 25 (8.77%) | 9 (5.49%) | 8 (4.68%) |
| Insulin dependent | 253 (3.6%) | 75 (1.88%) | 101 (4.83%) | 49 (6.96%) | 28 (9.33%) | 14 (3.12%) | 10 (3.51%) | 4 (2.44%) | 3 (1.75%) |
| Hypertension | 2189 (30.9%) | 1100 (27.59%) | 724 (34.62%) | 275 (39.06%) | 90 (30%) | 113 (25.17%) | 82 (28.77%) | 31 (18.9%) | 37 (21.64%) |
| Sleep apnoea | 857 (12.1%) | 449 (11.26%) | 221 (10.57%) | 155 (22.02%) | 32 (10.67%) | 21 (4.68%) | 19 (6.67%) | 2 (1.22%) | 13 (7.6%) |
| Not on CPAP | 949 (13.4%) | 529 (13.27%) | 297 (14.2%) | 76 (10.8%) | 35 (7.8%) | 25 (8.77%) | 10 (6.1%) | 3 (1.75%) |
centres where the facility was not treating COVID-19 patients (1618 patients; 21%). Testing of staff was performed in 67 centres (2144 patients; 27.8%).

**Postoperative COVID-19**

Of the 42 countries, 34 countries had at least one peak of COVID-19 during the study period (Table 5). A total of 6092 (79%) patients were entered into the database from these countries [23].

Forty-three patients (0.56%) developed symptomatic COVID-19 postoperatively. These patients were from Mexico (n = 8), Italy (n = 5), Egypt (n = 4), India (n = 4), Saudi Arabia (n = 4), Turkey (n = 4), Argentina (n = 3), the Netherlands (n = 3), Brazil (n = 2), Iran (n = 2), Israel (n = 2), Ecuador (n = 1), and UK (n = 1). Thirty-eight had undergone elective primary BS; two had undergone revisional BS, and three had undergone emergency surgery. Further attributes for patients who developed symptomatic COVID-19 postoperatively are described in Table 6.

Majority of these were either CD grade I (n = 29; 67.4%) or grade II (n = 11; 25.6%) complications. There were two CD grade IV (4.65%) and one CD grade V (2.32%) complications. Thus, there was one mortality due to COVID-19 in this study. This patient was a 35-year-old female, who had a BMI of 70.0 kg/m² along with, T2D on insulin, hypertension, OSA, hypercholesterolaemia, and previous history of deep vein thrombosis and underwent LOAGB. This patient had tested negative on RT-PCR and was recommended self-isolation for 2 weeks before surgery. She was discharged home the day after surgery and presented 10-days later with COVID-19 pneumonia. The initial surgery for this patient had been performed in a small-sized district general hospital which also treated COVID-19 patients concurrently. This patient had surgery during the top tertile of SARS-CoV-2 infection incidence for the country.

**Factors Associated with Symptomatic Postoperative COVID-19 (Table 6)**

On univariate analysis of biological plausible variables, only non-white ethnicity was significantly associated with symptomatic post-operative COVID-19 (p = 0.013; white, 25/5800; 58.1% of COVID-19-positive patients; non-white, 18/1904; 41.9% of COVID-19-positive patients).

The proportion of people who were advised to self-isolate was greater in the cohort that developed COVID-19 compared...
Table 2  30-day morbidity and mortality of elective primary BS, elective revisional BS, and emergency procedures

| Highest grade | Primary surgery | Revisional surgery | Emergency surgery |
|---------------|----------------|--------------------|-------------------|
|               | All primary procedures | All revisional procedures | Conversional surgery | Others |
|               | 7084 | 449 | 285 | 164 | 171 |
| Clavien Dindo grade I | 166 (2.34%) | 15 (3.34%) | 11 (3.86%) | 4 | 12 (7.02%) |
| Clavien Dindo grade II | 136 (1.92%) | 11 (2.45%) | 6 (2.11%) | 5 | 11 (6.43%) |
| Clavien Dindo grade IIIa | 33 (0.47%) | 8 (1.78%) | 5 (1.75%) | 3 | 1 (0.58%) |
| Clavien Dindo grade IIIb | 95 (1.34%) | 13 (2.9%) | 8 (2.81%) | 5 | 10 (5.85%) |
| Clavien Dindo grade IVa | 32 (0.45%) | 5 (1.11%) | 4 (1.4%) | 1 | 1 (0.58%) |
| Clavien Dindo grade IVb | 7 (0.1%) | 1 (0.22%) | 1 (0.35%) | 0 | 0 |
| Clavien Dindo grade V | 10 (0.14%) | 0 | 0 | 0 | 0 |
| All complications | 479 (6.76%) | 53 (11.8%) | 35 (12.2%) | 18 | 35 (20.46%) |
| Clavien Dindo grade I and II | 302 (4.26%) | 26 (5.79%) | 17 (5.96%) | 9 | 23 (13.45%) |
| Clavien Dindo grade III, IV, V | 177 (2.50%) | 27(6.01%) | 18 (6.31%) | 9 | 12 (7.01%) |
| COVID infection | COVID-19 | 20 (0.5%) | 0 | 2 | 3 (1.75%) |
| Specific complications | Bleeding | 120 (1.69%) | 9 (2%) | 5 (1.75%) | 4 | 0 |
| | Leak from gastrointestinal tract | 50 (0.71%) | 9 (2%) | 8 (2.81%) | 1 | 2 (1.17%) |
| | Wound infection | 42 (0.59%) | 11 (2.45%) | 4 (1.4%) | 7 | 6 (3.51%) |
| | Postoperative pneumonia (not otherwise specified) | 15 (0.21%) | 3 (0.67%) | 2 (0.7%) | 1 | 3 (1.75%) |
| | DVT | 3 (0.04%) | 0 | 0 | 0 | 1 (0.58%) |
| | PE | 7 (0.1%) | 0 | 0 | 0 | 0 |
| | Othera | 244 (3.44%) | 32 (7.13%) | 22 (7.72%) | 9 | 27 (15.79%) |
to those who did not develop COVID-19 (60.5%; 26/43 vs. 44.1%; 3290/7460, p = 0.03). Similarly, there was no difference in the proportion of patients who underwent BS in hospitals also looking after COVID-19 patients as compared to those who weren’t (74.4%; 32/43 vs 79.0%; 6054/7661).

Table 3   Univariate and logit regression analysis (7687 observation) for the risk of postoperative surgical complications within 30 days. *** p < 0.01, ** p < 0.05, * p < 0.1

|                          | Univariate analysis | Regression analysis |
|--------------------------|---------------------|---------------------|
|                          | No complication     | Complication        | p value | Odds ratio | Confidence intervals |
|                          | (7137 patients)     | (567 patients)      |         |            |                      |
| Age (year increase)      | 40.52 ± 11.8        | 43.14 ± 12          | < 0.001 | 1.008*     | 1.000–1.017          |
| Sex = male               | 1822 (25.5%)        | 175 (30.8%)         | 0.02    | 1.259**    | 1.033–1.534          |
| BMI (unit increase)      | 42.5 ± 7.3          | 41.9 ± 8.4          | 0.71    | 0.993      | 0.981–1.006          |
| Non-white                | 1755 (24.9%)        | 129 (22.8%)         | 0.26    | 1.020      | 0.797–1.305          |
| Type 2 diabetes mellitus| Diet controlled     | 398 (5.6%)          | 41 (7.2%)| 0.001      | 1.141                | 0.800–1.630          |
|                          | Oral medication     | 790 (11.1%)         | 54 (9.5%)|            | 0.681**              | 0.497–0.931          |
|                          | Insulin dependent   | 233 (3.3%)          | 37 (6.5%)|            | 1.451*               | 0.987–2.134          |
| Hypertension             | 1434 (20.1%)        | 161 (28.4%)         | < 0.001 | 1.083      | 0.879–1.334          |
| Sleep apnoea             | Not on CPAP         | 802 (11.2%)         | 89 (15.7%)| 0.001      | 1.107                | 0.842–1.457          |
|                          | on CPAP             | 902 (12.6%)         | 85 (15%) | 0.107      | 1.395**              | 1.076–1.809          |
| Hypercholesterolemia     | 1434 (20.1%)        | 161 (28.4%)         | < 0.001 | 1.440***   | 1.161–1.786          |
| Other co-morbidities     | 1988 (27.9%)        | 204 (36%)           | < 0.001 | 1.253**    | 1.038–1.513          |
| Smoking status (past or current) | 3755 (52.6%)   | 233 (41.1%)         | < 0.001 | 1.253**    | 1.038–1.513          |
| Surgery category reference — primary LSG | 136 (1.91%)       | 35 (6.17%)          | < 0.001 | 3.089***   | 1.983–4.814          |
| Emergency surgery        | 396 (5.5%)          | 53 (9.3%)           |         | 1.927***   | 1.374–2.701          |
| Revisional surgery       | 1924 (27%)          | 167 (29.5%)         |         | 1.219*     | 0.978–1.521          |
| RYGB                     | 651 (9.1%)          | 54 (9.5%)           |         | 1.244      | 0.902–1.716          |
| Other primary surgeries  | 275 (3.9%)          | 25 (4.4%)           |         | 1.492*     | 0.931–2.392          |
| Hospital size reference < 200 beds | 2127 (29.8%)       | 134 (23.6%)         | < 0.001 | 1.062      | 0.874–1.290          |
| Hospital capacity (beds) |                    |                    |         |            |                      |
| 200–499                  | 2156 (30.2%)        | 161 (28.4%)         |         | 1.068      | 0.818–1.395          |
| 500–999                  | 1886 (26.4%)        | 194 (34.2%)         |         | 1.140      | 0.841–1.545          |
| 1000–1999                | 691 (9.7%)          | 64 (11.3%)          |         | 1.191      | 0.831–1.707          |
| > 2000                   | 277 (3.9%)          | 14 (2.5%)           |         | 0.735      | 0.383–1.409          |
| Hospital category reference — district general | 2247 (31.5%)     | 145 (25.6%)         | < 0.001 | 1.431***   | 1.105–1.852          |
| Hospital category       | Teaching hospital   | 2254 (31.6%)        | 217 (38.3%)|         | 1.431***   | 1.105–1.852          |
|                          | University hospital | 2636 (36.9%)        | 205 (36.2%)|         | 1.088      | 0.836–1.414          |
| Surgeon experience reference < 500 procedures | 1129 (15.8%)      | 110 (19.4%)         | < 0.001 | 1.167      | 0.862–1.581          |
| Surgeon experience (procedures) |                    |                    |         |            |                      |
| 500–999                  | 827 (11.6%)         | 35 (6.2%)           |         | 0.754**    | 0.587–0.968          |
| 1000–2000                | 4264 (59.7%)        | 322 (56.8%)         |         |            |                      |
| > 2000                   | 917 (12.8%)         | 100 (17.6%)         |         | 0.434***   | 0.285–0.659          |
The Temporal Relationship Between the Country Incidence of COVID-19 and the Reported Post-BS Symptomatic COVID-19 Cases (Fig. 1)

With regard to the incidence of COVID-19 for individual countries, data from Ecuador, Iran, and Turkey were excluded from this analysis due to the absence of an obvious peak during the study period.

Symptomatic postoperative COVID-19 was more likely to develop (0.7%; 34/4674 cases) when all/part of the postoperative 30-day follow-up was within the top tertile of SARS-CoV-2 infection incidence for that country as opposed to when the incidence was in the bottom two tertiles (0.1%; 2/1924 cases). This difference was statistically significant (p < 0.001).

Hospital and Surgeon Characteristics

Data was equally represented from district general hospitals vs. teaching hospitals vs. university hospitals (2392 (31%) vs. 2471 (32.1%) vs. 2841 (36.9%) patients). The majority of the data were from hospitals with a bed capacity of < 1000 beds—5152 (66.9%) patients. A majority of the surgeons had performed between 1000 and 2000 procedures — 4586 (59.5%).

Discussion

This is the biggest study on patients undergoing any non-cancer surgery during the pandemic. This study showed that elective BS performed during the COVID-19 pandemic is probably safe with low 30-day morbidity and mortality and very low risk of symptomatic COVID-19, most of which were mild severity infections. This study also identified the factors associated with 30-day complications and symptomatic COVID-19 post-BS. These findings should reassure patients and health care providers regarding the safety of BS during the COVID-19 pandemic.

The burden of the pandemic has been uneven across the globe and also fluctuated widely from month to month within regions. At times, the healthcare systems have been too overwhelmed to allow for any elective surgery to take place.
Table 5  Country-wise reporting of cases and the relationship of the peak incidence of COVID-19 to the study period (1st May–30th Nov). (Based on https://github.com/CSSEGISandData/COVID-19/tree/master/csse_covid_19_data/csse_covid_19_time_series accessed 01/12/2020 at 14:00 GMT). Shaded lines represent countries that did not have a peak of COVID-19 incidence during the study period.

| Country            | Continent       | No. of BMS | Postoperative symptomatic COVID-19 | Peak     | Timing of peak |
|--------------------|-----------------|------------|------------------------------------|----------|----------------|
| Andorra            | Europe          | 16         |                                    | 22/10/20 | during         |
| Argentina          | South America   | 116        | 3                                  | 13/10/20 | during         |
| Australia          | Australia       | 124        |                                    | 30/07/20 | during         |
| Belgium            | Europe          | 114        |                                    | 25/10/20 | during         |
| Brazil             | South America   | 266        | 2                                  | 02/08/20 | during         |
| China              | Asia            | 28         |                                    | 09/02/20 | before         |
| Colombia           | South America   | 52         |                                    | 12/08/20 | during         |
| Croatia            | Europe          | 11         |                                    | 29/11/20 | during         |
| Ecuador            | South America   | 53         | 1                                  | >30/11/20| after          |
| Egypt              | Africa          | 156        | 4                                  | 17/06/20 | during         |
| Finland            | Europe          | 5          |                                    | 13/04/20 | before         |
| France             | Europe          | 370        |                                    | 31/10/20 | during         |
| Germany            | Europe          | 423        |                                    | 01/04/20 | before         |
| Greece             | Europe          | 142        |                                    | 14/11/20 | during         |
| India              | Asia            | 290        | 4                                  | 13/09/20 | during         |
| Iran               | Asia            | 171        | 2                                  | >30/11/20| after          |
| Ireland            | Europe          | 67         |                                    | 18/10/20 | during         |
| Israel             | Asia            | 160        | 2                                  | 23/07/20 | during         |
| Italy              | Europe          | 1223       | 5                                  | 12/11/20 | during         |
| Jordan             | Asia            | 26         |                                    | 15/11/20 | during         |
| Lebanon            | Asia            | 22         |                                    | 09/11/20 | during         |
| Lithuania          | Europe          | 75         |                                    | >30/11/20| after          |
| Malaysia           | Asia            | 11         |                                    | >30/11/20| after          |
| Mexico             | North America   | 754        | 8                                  | 24/07/20 | during         |
| Netherlands        | Europe          | 772        | 3                                  | 25/10/20 | during         |
| Oman               | Asia            | 2          |                                    | 07/07/20 | during         |
| Pakistan           | Asia            | 17         |                                    | 14/06/20 | during         |
| Poland             | Europe          | 108        |                                    | 11/11/20 | during         |
| Portugal           | Europe          | 168        |                                    | 16/11/20 | during         |
| Romania            | Europe          | 61         |                                    | 12/08/20 | during         |
| Russia             | Europe/Asia     | 19         |                                    | 16/05/20 | during         |
| Saudi Arabia       | Asia            | 107        | 4                                  | 23/06/20 | during         |
| Singapore          | Asia            | 28         |                                    | 01/05/20 | during         |
| Slovenia           | Europe          | 11         |                                    | 14/11/20 | during         |
| Spain              | Europe          | 289        |                                    | 01/11/20 | during         |
| Sweden             | Europe          | 32         |                                    | 14/06/20 | during         |
| Syria              | Asia            | 25         |                                    | 22/08/20 | during         |
| Turkey             | Europe/Asia     | 846        | 4                                  | >30/11/20| after          |
| United Arab Emirates| Asia           | 158        |                                    | 19/05/20 | during         |
| United Kingdom     | Europe          | 263        | 1                                  | 03/11/20 | during         |
| United States of America | North America | 104        |                                    | 21/07/20 | during         |
| Venezuela          | South America   | 19         |                                    | 02/09/20 | during         |
However, as is evident from our study, there have also been times when some surgical teams have had a more favourable pandemic condition and the resources to carry out elective surgery such as BS. This is probably a result of the massive global effort on the development of consensus guidelines and prioritisation criteria on safe resumption of BS [4, 6, 24]. But there is little data on the safety of the BS during the pandemic with the adoption of some or all of these recommendations. In particular, there is a need to understand the efficacy of protocols in identifying asymptomatic SARS-CoV-2 infected patients and reducing viral transmission within healthcare facilities. We also need to understand if other changes imposed by the pandemic such as recommendations to avoid laparoscopic surgery without any definite evidence [25]; deskilling of the surgical teams; recommendations to shorten hospital stay of patients and increased use of telemedicine [4, 6]; and recommendations to operate on highest risk patients first [24] have impacted the safety of BS.

In our first report from this dataset [19], we had concluded that the 30-day morbidity and mortality of elective primary BS at 6.8% and 0.05%, respectively, seemed similar to the pre-pandemic figures. These figures have remained broadly unchanged at 6.76% and 0.14% even though we now have 7084 elective primary BS patients as opposed to 2001 in our initial report [19]. These figures appear similar to large pre-pandemic BS datasets [26–28].

**Table 6** Factors associated with symptomatic postoperative COVID-19

| Factor                                      | Symptomatic postoperative COVID-19 | p value |
|---------------------------------------------|-----------------------------------|---------|
|                                             | Yes                               | No      |         |
| Non-white ethnicity                         | 18 (41.8%)                        | 1886 (24.6%) | 0.013   |
| Preoperative self-isolation                 | 26 (60.5%)                        | 3290 (44.1%) | 0.031   |
| Preoperative testing                        | 35 (81.4%)                        | 6100 (79.6%) | 0.774   |
| Hospitals also treating COVID-19 patients   | 32 (74.4%)                        | 6054 (79%)  | 0.46    |
| Use of PPE in theatre                       | 23 (0.7%)                         | 4319 (99.5%) | 0.193   |

**Fig. 1** The temporal relationship between the country incidence of COVID-19 and the reported post-BS symptomatic COVID-19 cases. Daily cumulative infection data were downloaded from John’s Hopkins University git repository [19] and differentiated to obtain daily numbers of new infection cases. In order to analytically define peak maxima of new infections, data curves for each country were fed through a low-pass Butterworth filter. Maxima were automatically detected if local maxima had a width of at least 7 days and reached at least 15% of the maximum number of infections of the country. Day of surgery is indicated for each SARS-CoV2 positive patient with a dot. The darker shaded area after each dot indicates the 30-day follow-up period. The study period started at 01/05/2020 and ended at 30/11/2020. The top three panels were used to show this data due to the differences in the scale of incidence of SARS-CoV-2 infection in respective countries. The bottom panel illustrates the tertiles and infections/ day in Argentina. Patient A had date of surgery and 30-day follow-up within the lower and middle tertile. Patient B had the 30-day follow-up in the top tertile and Patient C had date of surgery and 30-day follow-up in the top tertile of the number of cases.
It would be particularly interesting to know what percentage of patients undergoing BS during the pandemic develops symptomatic COVID-19 postoperatively and the outcomes of those who were inadvertently operated on whilst positive for SARS-CoV-2 at the time of the surgery. This makes the emergency cohort in our study of particular interest especially because we know that patients with perioperative SARS-CoV-2 have significantly higher morbidity and mortality [1]. At the same time, the outcomes of the different cohorts — primary elective BS, primary revisional BS, and emergency surgery groups — have been clearly and separately presented in this study as they have different characteristics. Of note, two emergency patients in this study were positive for SARS-CoV-2 at the time of the surgery — one developed COVID pneumonia and the other remained symptomatic. Neither of the two died.

The incidence of symptomatic COVID-19 postoperatively was low in our study, and most of these were mild (CD grade I or II). This may be due to several factors such as low disease burden in the community or effective preoperative strategies or measures to reduce in-hospital transmission of the virus. Overall, it does suggest that measures adopted locally by bariatric surgery teams were effective in preventing postoperative COVID-19. The single COVID-related mortality reported was a high-risk patient with severe obesity, multiple co-morbidities who had also tested negative for SARS-CoV-2 infection preoperatively. This patient presented 10 days after surgery. Since the median incubation period of COVID-19 is around 4 days [29], this patient probably acquired the virus postoperatively. This might suggest a need to develop protocols for postoperative protection for high-risk patients. Such an approach would be supported by another study on benign surgery (Trauma and Orthopaedics) by Karayiannis and colleagues [30] where authors recommended the development of effective strategies to reduce “post-operative exposure to the virus”. However, specific lessons that were learnt by the team where this unfortunate event happened were not captured in this study. This needs to be examined in future studies on this topic. Similarly, based on just one mortality, it would be unreasonable to conclude that patients with significant co-morbidities should not be offered BS during the pandemic.

Blood coagulation disorders continue to be an area of much interest during this pandemic [31, 32]. Patients in this study who died of pulmonary embolism or mesenteric venous thrombosis were not positive for SARS-CoV-2. We could not obtain detailed information on the patient who died of multiorgan failure (NOS) as the patient was treated in a different facility and the original surgeon could not provide us with all the details. However, the surgeon did not report this patient as having suffered from postoperative COVID-19.

With regard to perioperative strategies, there is data on preoperative RT-PCR testing and COVID-free pathways in the context of cancer surgery [12, 13] but not for patients undergoing benign surgery. In this study, preoperative viral testing or surgeries in a facility that was not treating COVID-19 patients were not associated with less postoperative symptomatic COVID-19 infection. Interestingly, we found that those who were advised preoperative self-isolation were significantly more likely to develop postoperative symptomatic COVID-19. This could be due to an overall higher viral burden in those communities at the time of preoperative consultation/counselling. One could hypothesise that surgical teams in areas with higher viral community load were more likely to recommend preoperative self-isolation. It is a counterintuitive association that needs examination in further focussed studies. Furthermore, the true protective effect of preoperative self-isolation may have been masked by the preoperative testing for SARS-CoV-2 infection as the majority of the patients in this study underwent some form of testing.

The risk of developing postoperative symptomatic COVID-19 was greater when the surgery or part of the 30-day follow-up occurred during the peak of COVID-19 incidence for that country. This might suggest a need for measures to reduce postoperative viral exposure. However, this information cannot be used to determine the level of pandemic burden when it would be safe to perform BS in any particular region since this information can only be worked out retrospectively with our methodology (BS was safer when the country incidence was in the lower two tertiles as opposed to the higher tertile).

The data from this study supports data from previous studies that patients of non-white ethnicity were at a higher risk of symptomatic COVID-19 postoperatively [33]. This may be due to several factors as non-white patients in this study come from countries with diverse healthcare systems and disease burdens [34]. Even within the same country, non-white populations may be at higher risk due to socio-economic and cultural factors. In light of these findings, additional and more stringent COVID-19-specific perioperative protocols could be considered for non-white patients who are undergoing BS. These could include stricter preoperative testing and self-isolation; more stringent precautions such as mask-wearing; segregation from emergency patients; use of PPE in the healthcare facility; easy access to surgical teams postoperative; and postoperative self-isolation.

This is the first multinational study to examine complications of BS and the predictors of these complications. In this study, we found that increasing age, male sex, or current or former smoking predicted the severity of complications following BS. This has previously been documented in the literature [35]. Emergency and revisional bariatric surgery were associated with a higher risk of postoperative complications as was primary RYGB. This reflects the complexity of emergency and revisional BS. Similarly, a higher risk of complications with RYGB has been previously reported [36]. It is worth
noting that though complication rates were higher for both LRYGB and LOAGB (compared to LSG), this difference was only significant for LRYGB after adjustment for risk factors. This data also confirmed a higher risk of complications with insulin-treated T2D, untreated obstructive sleep apnoea, hypertension, and hypercholesterolaemia. The association of T2D with increased morbidity and mortality after BS has been previously reported [36]. The data supported that increasing surgical experience was associated with a lower risk of postoperative complications and that type of hospital affected the risk of postoperative complications.

The findings of this study might also be relevant to the wider category of minor and intermediate-risk elective surgical procedures in the context of the pandemic [37]. Until conclusive research on this subject, the findings of this study might suggest a role for postoperative isolation and additional protocols in non-white patients.

**Study Limitations**

This study has several limitations. It only includes data of participating centres and may therefore not represent the real global picture. The outcomes of this study are only applicable to the study population and cannot be extrapolated to populations whose composition is different from the current study in terms of age, sex, and racial characteristics. Also, data reported from countries was not proportional to the prevalence of pre-pandemic bariatric surgery in those countries. Notably, the numbers from the USA and Brazil are fewer than expected. This may be due to several factors such as the pandemic burden in those countries at the time of the study or engagement of surgical teams within those countries with this study.

There was no data available for 30 patients. However, complete 30-day follow-up data on 99.6% of the patients should be considered satisfactory. Also, though all reasonable care was undertaken to ensure our collaborators knew the importance of submitting all consecutive patients during the study period, we cannot be certain of that. At the same time, repeated reminders on the importance of this should have encouraged it. Although data on self-isolation has been presented, no attempts were made to capture adherence to self-isolation or mode of self-isolation (co-self-isolation with household).

Only patients with symptomatic infection were reported by the collaborators. The local prevalence data and incidence of postoperative SARS-CoV-2 infection have been presented over the entire study period and have not been divided into monthly periods. Finally, data on complications were self-reported by surgical teams and may therefore not represent an accurate picture. There remains the possibility that complications were underreported by collaborators. Authors though hope that anonymous data collection would have reduced any underreporting of complications. Furthermore, no attempt was made by the authors to identify data from individual participants in this global collaborative study. Data were only analysed as a whole. We further encouraged reporting of complications by asking collaborators to actively confirm the absence of complications at the 30-day mark.

**Study Strengths**

The study has several strengths such as a large sample size, the global reach of the study, and extensive data profiling. Almost 80% of the data was collected from countries that had at least one peak of COVID-19 during the study period. With 99.6%, 30-day follow-up data, authors have high confidence that these findings represent true figures in the participating centres. The use of a validated CD system of reporting complications for such a large dataset further adds to the robustness of our study. The large sample size allowed the examination of predictors of complications and postoperative symptomatic COVID-19.

**Conclusion**

Bariatric and metabolic surgery can be performed safely during the COVID-19 pandemic with appropriate perioperative protocols. Non-white ethnicity and having surgery during a local peak of COVID-19 for that country were associated with a greater risk of symptomatic COVID-19 postoperatively. There was no relationship between preoperative testing for COVID-19/ preoperative self-isolation and incidence of symptomatic postoperative COVID-19 perhaps suggesting that the measures to reduce the postoperative viral exposure are equally important.

**Supplementary Information** The online version contains supplementary material available at https://doi.org/10.1007/s11695-021-05493-9.

**Acknowledgements** GVG acknowledges from support the NIHR Birmingham ECMC, NIHR Birmingham SRMRC, Nanocommons H2020-EU (731032), and the NIHR Birmingham Biomedical Research Centre and the MRC Health Data Research UK (HDRUK/CFC/01), an initiative funded by UK Research and Innovation, Department of Health and Social Care (England) and the devolved administrations, and leading medical research charities. We thank Naomi Campton (Translational Research and DatabaseManager at University of Birmingham) for providing the support with database maintenance and troubleshooting.

GENEVA Collaborators, Michal Pędzisz, Piotr Major, Piotr Zarzycki, Athanasios Pantelis, Dimitris P. Laptas, Georgios Stravodimos, Chris Matthys, Marc Focquet, Wouter Vleeschouwers, Antonio G Spaventa, Carlos Zerrwiek, Antonio Vitiello, Giovanna Berardi, Mario Musella, Alberto Sanchez-Meza, Felipe J Cantu Jr, Fernando Mora, Marco A Cantu, Abhishek Katakwar, D Nageshwar Reddy, Haitham Elmaleh, Mohammad Hassan, Abdelrahman Elghandour, Mohey Elbanna, Ahmed Osman, Athar Khan, Laurent layani, Naolini kiran, Andrey Velikorechin, Maria Soloyeva, Hamid Melali, Shahab Shahabi, Ashish Agrawal, Apoorv Shrivastava, Ankur Sharma, Bhavya Narwaria, Mahendra Narwaria, Asnat Raziel, Nasser
Conflict of Interest

The authors declare no competing interests.

Human and Animal Rights and Informed Consent

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study by the respective comparable ethical standards.

Funding

This study is funded by Bariatric Unit, University Hospital Birmingham NHS Foundation Trust.

Declarations

Human and Animal Rights and Informed Consent

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study by the respective GENEVA collaborators.

Conflict of Interest

The authors declare no competing interests.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Collaborative C. Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study. Lancet. 2020;396(10243):27–38.
2. Collaborative C. Elective surgery cancellations due to the COVID-19 pandemic: global predictive modelling to inform surgical recovery plans. Br J Surg. 2020;107(11):1440–9.
3. Ammian A, Kermansaravi M, Azzizi S, et al. Bariatric surgical practice during the initial phase of COVID-19 outbreak. Obes Surg. 2020;30(9):3624–7.
4. Pouwels S, Omar I, Aggarwal S, et al. The first modified Delphi consensus statement for resuming bariatric and metabolic surgery in the COVID-19 times. Obes Surg. 2021;31(1):451–6.
5. Daigle CR, Augustin T, Wilson R, et al. A structured approach for safely reintroducing bariatric surgery in a COVID-19 environment. Obes Surg. 2020;30(10):4159–64.
6. Aggarwal S, Mahawar K, Khaitan M, et al. Obesity and metabolic surgery society of India (OSS) recommendations for bariatric and metabolic surgery practice during the COVID-19 pandemic. Obes Surg. 2020;30(12):5101–7.
7. Di Saverio S et al. Coronavirus pandemic and colorectal surgery: practical advice based on the Italian experience. Color Dis. 2020;22(6):625–34.
8. Kovoor JG, Tivey DR, Williamson P, et al. Screening and testing for COVID-19 before surgery. ANZ J Surg. 2020;90(10):1845–56.
9. Demiroz A, Aydin S, Yalcin CE, et al. Risk assessment of surgical interventions performed on non-infected patients during COVID-19 pandemic. Cureus. 2020;12(12):e11682.
10. Chang JS, Wignadassen W, Pradhan J, et al. Elective orthopaedic surgery with a designated COVID-19-free pathway results in low perioperative viral transmission rates. Bone Jt Open. 2020;1(9):562–7.
11. Zahra W, Dixon JW, Mirtorabi N, et al. Safety evaluation of a strategy to restart elective orthopaedic surgery during the de-escalation phase of the COVID-19 pandemic. Bone Jt Open. 2020;1(8):450–6.
12. Collaborative C. Preoperative nasopharyngeal swab testing and postoperative pulmonary complications in patients undergoing elective surgery during the SARS-CoV-2 pandemic. Br J Surg. 2021;108(1):88–96.
13. Glasbey JC, Nepogodiev D, Simoes JFF, et al. Elective cancer surgery in COVID-19-free surgical pathways during the SARS-CoV-2 pandemic: an international, multicenter, comparative cohort study. J Clin Oncol. 2021;39(1):66–78.
14. Popkin BM, du S, Green WD, et al. Individuals with obesity and COVID-19: a global perspective on the epidemiology and biological relationships. Obes Rev. 2020;21(11):e13128.
15. Wynants L et al. Prediction models for diagnosis and prognosis of COVID-19 infection: systematic review and critical appraisal. Bmj. 2020;369:m1328.
16. Flint SW, Tahrani AA. COVID-19 and obesity-lack of clarity, guidance, and implications for care. Lancet Diabetes Endocrinol. 2020;8(6):474–5.
17. Le Brocq S et al. Obesity and COVID-19: a call for action from people living with obesity. Lancet Diabetes Endocrinol. 2020;8(8):652–4.
18. Flint SW, Brown A, Tahrani AA, et al. Cross-sectional analysis to explore the awareness, attitudes and actions of UK adults at high risk of severe illness from COVID-19. BMJ Open. 2020;10(12):e045309.
19. Singhal R, Tahrani AA, Ludwig C, et al. Global 30-day outcomes after bariatric surgery during the COVID-19 pandemic (GENEVA): an international cohort study. Lancet Diabetes Endocrinol. 2021;9(1):7–9.
20. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–13.
21. Harris PA et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95:103208.
22. Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–81.
23. Git Hub, C.C.. COVID-19/cesse_covid_19_data/cesse_covid_19_time_series at master [cited 2021 07/01/2021]; Available from: https://github.com/CSSEGISandData/COVID. Accessed 01/12/2020.
24. Rubino F, Cohen RV, Mingrone G, et al. Bariatric and metabolic surgery during and after the COVID-19 pandemic: DSS recommendations for management of surgical candidates and postoperative patients and prioritisation of access to surgery. Lancet Diabetes Endocrinol. 2020;8(7):640–8.
25. Agrawal V, Sharma D. Initial advice to avoid laparoscopic surgery due to fear of COVID-19 virus transmission: Where was the evidence? Br J Surg. 2020;107(10):e418.
26. Alizadeh RF, Li S, Gambhir S, et al. Laparoscopic sleeve gastrectomy or laparoscopic gastric bypass for patients with metabolic syndrome: an MBSAQIP analysis. Ann Surg. 2019;350(1):1108–12.
27. Benotti P, Wood GC, Winegar DA, et al. Risk factors associated with mortality after Roux-en-Y gastric bypass surgery. Ann Surg. 2014;259(1):123–30.
28. Stenberg E, Szabo E, Ågren G, et al. Closure of mesenteric defects in laparoscopic gastric bypass: a multicentre, randomised, parallel, open-label trial. Lancet. 2016;387(10026):1397–404.
29. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–20.
30. Karayiannis PN, Roberts V, Cassidy R, et al. Thirty-day mortality following trauma and orthopaedic surgery during the peak of the COVID-19 pandemic: a multicentre regional analysis of 484 patients. Bone Jt Open. 2020;1(7):392–7.
31. Janardhan V, Janardhan V, Kalousek V. COVID-19 as a blood clotting disorder masquerading as a respiratory illness: a cerebrovascular perspective and therapeutic implications for stroke thrombectomy. J Neuroimaging. 2020;30(5):555–61.
32. Cheung S et al. Superior mesenteric artery thrombosis and acute intestinal ischemia as a consequence of COVID-19 infection. Am J Case Rep. 2020;21:e925753.
33. Renelus BD, et al. Racial disparities in COVID-19 hospitalization and in-hospital mortality at the height of the New York City pandemic. J Racial Ethn Health Disparities, 2020; p. 1-7.
34. Bhanderi S, Alam M, Matthews JH, et al. Influence of social deprivation on provision of bariatric surgery: 10-year comparative ecological study between two UK specialist centres. BMJ Open. 2017;7(10):e015453.
35. Finks JF, Kole KL, Yenumula PR, et al. Predicting risk for serious complications with bariatric surgery: results from the Michigan Bariatric Surgery Collaborative. Ann Surg. 2011;254(4):633–40.
36. Birkmeyer NJ et al. Hospital complication rates with bariatric surgery in Michigan. Jama. 2010;304(4):435–42.
37. Kristensen SD, Knuuti J, Saraste A, et al. 2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: the joint task force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). Eur Heart J. 2014;35(35):2383–431.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.